The current financial score of Vanda Pharmaceuticals Inc is 7.18. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 50.53M, representing a year-over-year decrease of 3.92%, while its net profit experienced a year-over-year decrease of 129.77%.
The current valuation score of Vanda Pharmaceuticals Inc is 8.08. Its current P/E ratio is -1.26, which is -8463.98% below the recent high of 105.42 and -5960.75% above the recent low of -76.39.
The current earnings forecast score of Vanda Pharmaceuticals Inc is 7.50. The average price target is 12.19, with a high of 20.00 and a low of 5.75.
The current price momentum score of Vanda Pharmaceuticals Inc is 3.41. Currently, the stock price is trading between the resistance level at 5.52 and the support level at 4.82, making it suitable for range-bound swing trading.
The current institutional shareholding score of Vanda Pharmaceuticals Inc is 7.00. The latest institutional shareholding proportion is 78.40%, representing a quarter-over-quarter increase of 1.13%. The largest institutional shareholder is James Simons, holding a total of 3.44M shares, representing 0.03% of shares outstanding, with 17.06% increase in holdings.
The current risk assessment score of Vanda Pharmaceuticals Inc is 5.84. The company's beta value is 0.63. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.